Biomea Fusion ( NASDAQ:BMEA – Get Free Report ) ‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $40.00 target price on the stock.
Several other brokerages also recently commented on BMEA. Truist Financial upgraded Biomea Fusion from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a report on Friday, September 27th.
EF Hutton Acquisition Co. I raised Biomea Fusion to a “strong-buy” rating in a research report on Wednesday, October 9th. RODMAN&RENSHAW upgraded Biomea Fusion to a “strong-buy” rating in a report on Thursday, September 26th.
Barclays boosted their target price on Biomea Fusion from $9.00 to $11.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th.
Finally, Rodman & Renshaw raised shares of Biomea Fusion from a “neutral” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Thursday, September 26th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock.
Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $30.50.
View Our Latest Stock Analysis on Biomea Fusion Biomea Fusion Price Performance Biomea Fusion ( NASDAQ:BMEA – Get Free Report ) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.
94) by $0.03. On average, sell-side analysts expect that Biomea Fusion will post -3.
93 EPS for the current year. Insider Buying and Selling In other Biomea Fusion news, Director Michael J.M.
Hitchcock acquired 10,000 shares of the company’s stock in a transaction on Monday, September 30th. The shares were purchased at an average price of $10.06 per share, for a total transaction of $100,600.
00. Following the completion of the purchase, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $150,900. This represents a 200.
00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website . 27.
57% of the stock is currently owned by corporate insiders. Hedge Funds Weigh In On Biomea Fusion A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte.
Ltd. bought a new stake in shares of Biomea Fusion during the 2nd quarter worth about $36,000. High Net Worth Advisory Group LLC acquired a new stake in Biomea Fusion during the second quarter worth approximately $45,000.
Scientech Research LLC bought a new stake in shares of Biomea Fusion during the second quarter worth approximately $46,000. DRW Securities LLC acquired a new position in shares of Biomea Fusion in the second quarter valued at approximately $55,000. Finally, China Universal Asset Management Co.
Ltd. increased its stake in shares of Biomea Fusion by 64.9% during the third quarter.
China Universal Asset Management Co. Ltd. now owns 6,964 shares of the company’s stock worth $70,000 after purchasing an additional 2,741 shares during the period.
96.72% of the stock is owned by institutional investors. About Biomea Fusion ( Get Free Report ) Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Recommended Stories Five stocks we like better than Biomea Fusion Dividend Screener: How to Evaluate Dividend Stocks Before Buying Tesla Investors Continue to Profit From the Trump Trade When to Sell a Stock for Profit or Loss MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally Bank Stocks – Best Bank Stocks to Invest In Netflix Ventures Into Live Sports, Driving Stock Momentum Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.
com's FREE daily email newsletter ..
Business
HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA)
Biomea Fusion (NASDAQ:BMEA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $40.00 target price on the stock. Several other brokerages also recently commented on BMEA. Truist Financial upgraded Biomea Fusion from a “hold” rating to a “buy” [...]